Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | STS | P08842 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221063 | 1.00 | CYP2D6 (0.54) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL222877 | 1.00 | CYP2D6 (0.54) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL771264 | 0.93 | CYP2D6 (0.49) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL15472723 | 0.93 | CYP2D6 (0.49) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL17181765 | 0.93 | CYP2D6 (0.49) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL184777 | 0.93 | CYP2D6 (0.60) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL2298971 | 0.90 | CYP2D6 (0.49) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL28719877 | 0.88 | CYP2D6 (0.55) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL5447212 | 0.88 | CYP2D6 (0.55) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL19001727 | 0.88 | CYP2D6 (0.55) | CYP2D6GPR119MMP13KMT2ASTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| WO-2025149577-A1 | 18F-CXCR2 PET TRACER | JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) | 2025-07-17 | — | — | WO | disclosed |
| CN-115677601-B | Compound with anti-tumor activity and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2025-05-01 | — | — | US | disclosed |
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | CALICO LIFE SCIENCES LLC (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4476211-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-3405192-B1 | BRUTON'S TYROSINE KINASE INHIBITORS | ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO LTD (CN) | 2024-12-11 | — | — | EP | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| WO-2009052062-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052062-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
| EP-2039680-A1 | PROCESS FOR PRODUCING ESTER OR ALCOHOL | Mitsui Chemicals, Inc. (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-1987020-A1 | AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093364-A1 | AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-08-23 | — | — | WO | disclosed |
| EP-1278728-B1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | disclosed |
| EP-1278728-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| US-6451819-B2 | PYRROLIDINE-3-YL-SULFANYL, OR SUFONYL OR SUFINYL DERIVATIVES USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HOFFMANN-LA ROCHE INC. | 2002-09-17 | — | — | US | disclosed |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | HOFFMANN-LA ROCHE INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001081303-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREAMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, ERBB4 | CYP2D6 1479/4885GPR119 3369/4885MMP13 4376/4885 |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | CYP2D6 1233/4885GPR119 3678/4885MMP13 239/4885 |
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | PTPN1, PTPN2, PTPN5 | CYP2D6 1619/4885GPR119 1060/4885MMP13 2795/4885 |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | GRIN1, GRM1, GRIN2B | CYP2D6 1038/4885GPR119 418/4885MMP13 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.